Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Guggulsterone** is a phytosteroid isolated from the resin of the guggul plant (Commiphora mukul), primarily found in two stereoisomeric forms: E-guggulsterone and Z-guggulsterone[1][5]. It acts as a broad-spectrum ligand of steroid hormone receptors and is known for antagonizing the farnesoid X receptor (FXR), historically thought to reduce cholesterol synthesis in the liver, although clinical evidence does not support significant cholesterol-lowering effects[1][4]. Guggulsterone displays antagonist or partial agonist activity at several other nuclear receptors (mineralocorticoid, progesterone, glucocorticoid, androgen, and estrogen receptors), and acts as an agonist at the pregnane X receptor[1]. Experimental studies in cells and animals suggest anti-inflammatory, antiapoptotic, and antitumor activities, mediated through modulation of multiple signaling pathways (e.g., NF-kB, STAT3, PI3K/Akt, apoptosis regulators), but there is limited clinical evidence for these uses[3][4][7]. It is commonly present as an ingredient in nutritional supplements, especially those targeted at lipid disorders, inflammation, and purported weight management[7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guggulsterone.